This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Vigabatrin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Vigabatrin irreversibly inhibits the enzyme which breaks down GABA (gamma aminobutyric acid) in the brain.

  • should only be initiated by an epilepsy specialist

  • indicated only when all other appropriate antiepileptic complications have been ineffective or poorly tolerated. Vigabatrin should not be initiated as monotherapy. The exception to this advice is that vigabatrin remains first-line treatment for West's syndrome (infantile spasms) (1)

  • 1/3 of patients with epilepsy patients treated with vigabatrin have characteristic visual field defects (1). These visual field defects vary from severe and potentially disabling to asymptomatic. The visual field loss associated with vigabatrin appears to be irreversible

The summary of product characteristics must be consulted before prescribing this drug.

Reference:

  • 1) Current Problems in Pharmacovigilance (1999), 25, 13.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.